Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

DXR

Daxor Corp

Feb 11 • 09:38AM ET

12.65

+0.45 3.69 %

Healthcare • Medical Instruments & Supplies • USA • NASD

Feb 10, 8:06 AMDaxor Corporation announces plans to transition its primary regulatory status from Investment Company Act of 1940 reporting to Securities Exchange Act of 1934 reporting by the end of Q2 2026, aligning with its core diagnostic operating business.

Peers: BIO DHR BRKR TMO MMI QDEL A TRIB VRTX ILMN

| Held by: VTI

Scroll to Statements

Index	-	P/E	34.69	EPS (ttm)	0.36	Insider Own	57.67%	Shs Outstand	4.98M	Perf Week	0.40%
Market Cap	73.75M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.47M	Perf Month	-11.13%
Enterprise Value	74.01M	PEG	-	EPS next Q	-	Inst Own	1.45%	Short Float	0.27%	Perf Quarter	-1.17%
Income	1.80M	P/S	68.92	EPS this Y	-	Inst Trans	-1.13%	Short Ratio	1.41	Perf Half Y	11.16%
Sales	1.07M	P/B	1.77	EPS next Y	-	ROA	5.12%	Short Interest	0.01M	Perf YTD	-14.24%
Book/sh	7.15	P/C	-	EPS next 5Y	-	ROE	5.26%	52W High	14.76 -14.28%	Perf Year	75.21%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	-54.50% -	ROIC	5.01%	52W Low	6.55 93.13%	Perf 3Y	41.90%
Dividend Est.	-	EV/EBITDA	40.01	Sales past 3/5Y	62.70% -	Gross Margin	85.67%	Volatility	2.20% 4.12%	Perf 5Y	-7.93%
Dividend TTM	-	EV/Sales	69.17	EPS Y/Y TTM	3.43%	Oper. Margin	173.24%	ATR (14)	0.62	Perf 10Y	49.35%
Dividend Ex-Date	Jan 05, 2018	Quick Ratio	0.19	Sales Y/Y TTM	-97.00%	Profit Margin	168.48%	RSI (14)	47.49	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.19	EPS Q/Q	77.93%	SMA20	-1.38%	Beta	0.04	Target Price	22.00
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	144.72%	SMA50	-3.76%	Rel Volume	0.67	Prev Close	12.20
Employees	-	LT Debt/Eq	0.01	Earnings	-	SMA200	14.18%	Avg Volume	4.76K	Price	12.65
IPO	Jul 25, 1983	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	336	Change	3.69%

Date	Action	Analyst	Rating Change	Price Target Change
May-16-19	Initiated	Ascendiant Capital Markets	Buy	$20

Feb-10-26 08:00AM	Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business (GlobeNewswire)
Jan-23-26 08:00AM	Daxor Corporation Announces $9 Million Registered Direct Offering (GlobeNewswire) -8.13%
Nov-25-25 08:00AM	Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer (GlobeNewswire)
Oct-21-25 08:00AM	Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit (GlobeNewswire)
Oct-15-25 08:00AM	Daxor's New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25 (GlobeNewswire)
08:00AM	Loading…
Sep-30-25 08:00AM	Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA (GlobeNewswire) +6.21%
Sep-23-25 08:00AM	Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting (GlobeNewswire)
Sep-04-25 08:00AM	Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care (GlobeNewswire) +6.59%
Sep-03-25 08:00AM	Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-02-25 08:00AM	Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter (GlobeNewswire) -5.27%
Aug-12-25 08:00AM	Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available (GlobeNewswire) +12.78%
Aug-07-25 07:55AM	Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System (GlobeNewswire)
Jul-22-25 08:00AM	Daxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions (GlobeNewswire)
May-14-25 08:00AM	Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal (GlobeNewswire)
May-13-25 08:00AM	Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems (GlobeNewswire)
08:00AM	Loading…
May-07-25 08:00AM	Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology (GlobeNewswire)
May-06-25 08:00AM	Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance (GlobeNewswire)
Apr-22-25 08:00AM	Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions (GlobeNewswire)
Apr-17-25 08:00AM	Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025 (GlobeNewswire)
Apr-15-25 08:00AM	New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival (GlobeNewswire) -5.83%
Apr-10-25 08:00AM	Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer (GlobeNewswire)
Apr-02-25 08:00AM	Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo (GlobeNewswire)
Mar-28-25 08:00AM	Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks (GlobeNewswire)
Mar-04-25 04:55PM	Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024 (GlobeNewswire)
03:53PM	Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025 (GlobeNewswire)
09:00AM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
Feb-28-25 08:00AM	Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center (GlobeNewswire)
Feb-27-25 08:00AM	Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals (GlobeNewswire)
Feb-19-25 08:00AM	Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025 (GlobeNewswire)
Feb-18-25 08:00AM	Daxor to Exhibit at World's Largest Critical Care Conference (GlobeNewswire)
08:00AM	Loading…
Feb-14-25 08:00AM	Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment (GlobeNewswire)
Feb-13-25 08:00AM	New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care (GlobeNewswire)
Dec-18-24 08:00AM	Daxor Expands Its BVA-100 Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum (GlobeNewswire)
Oct-09-24 08:00AM	DAXOR'S INNOVATIVE BVA-100 BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24 (GlobeNewswire)
Oct-08-24 08:00AM	Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-27-24 05:00PM	Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device (GlobeNewswire)
Sep-19-24 08:00AM	Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 (GlobeNewswire)
Sep-12-24 08:00AM	Newly Published Review Highlights the Pivotal Role of Daxor's Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management (GlobeNewswire)
Sep-05-24 08:00AM	Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee (GlobeNewswire)
Sep-04-24 08:30AM	Leading Central Florida Hospital Implements Daxor's BVA-100 Blood Volume Diagnostic for Heart Failure Patient Care (GlobeNewswire) +5.40%
Sep-03-24 04:05PM	Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter (GlobeNewswire)
12:15PM	Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-29-24 08:00AM	Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network (GlobeNewswire) +21.25%
Aug-06-24 08:00AM	Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer (GlobeNewswire)
Aug-05-24 08:00AM	Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide (GlobeNewswire) +11.96%
Jul-24-24 08:00AM	Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer (GlobeNewswire)
Jul-11-24 08:00AM	Daxor Corporation's BVA-100 Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide (GlobeNewswire)
Jun-18-24 08:00AM	Daxor Corporation to Showcase the Benefits of BVA-100 Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting (GlobeNewswire)
Jun-05-24 08:00AM	Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-16-24 08:00AM	New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion (GlobeNewswire)
Apr-15-24 08:00AM	DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING'24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100 ) (GlobeNewswire)
Apr-10-24 08:00AM	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital (GlobeNewswire)
Apr-01-24 08:00AM	Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24 (GlobeNewswire)
Mar-28-24 10:38AM	Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-25-24 08:00AM	Daxor Corporation Acquires Volumex and Megatope From Its Existing Supplier Along With Glofil to Enhance Existing Suite of Diagnostics (GlobeNewswire) +6.74%
Mar-22-24 08:00AM	Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024 (GlobeNewswire)
Mar-18-24 02:18PM	Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 (GlobeNewswire)
02:18PM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
Mar-11-24 08:00AM	Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base (GlobeNewswire)
Mar-08-24 08:00AM	Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients (GlobeNewswire)
Feb-26-24 08:00AM	Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference (GlobeNewswire)
Feb-12-24 08:00AM	Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions (GlobeNewswire)
Feb-07-24 08:00AM	Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100 Blood Volume Diagnostic Across the U.S. at Existing Accounts (GlobeNewswire)
Jan-29-24 08:00AM	Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting (GlobeNewswire)
Jan-16-24 08:00AM	Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress (GlobeNewswire)
Jan-09-24 08:00AM	DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES (GlobeNewswire)
Jan-02-24 08:30AM	Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer (GlobeNewswire)
Nov-13-23 08:00AM	New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients (GlobeNewswire) +7.05%
Nov-09-23 08:00AM	Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume (GlobeNewswire)
Oct-13-23 08:00AM	Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting (GlobeNewswire)
Oct-11-23 08:00AM	New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100 Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting (GlobeNewswire)
Oct-04-23 08:00AM	Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program (GlobeNewswire)
Sep-27-23 08:00AM	Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023 (GlobeNewswire)
Sep-26-23 08:00AM	DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL23 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXORS BLOOD VOLUME DIAGNOSTIC (BVA-100®) (GlobeNewswire)
Sep-11-23 12:00PM	Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients (GlobeNewswire)
Sep-07-23 09:15AM	Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-28-23 04:15PM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
04:05PM	Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023 (GlobeNewswire)
Aug-10-23 08:00AM	JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100® (GlobeNewswire)
Jul-12-23 08:00AM	JACC-HF Study Compares Daxors BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients (GlobeNewswire)
Jul-11-23 08:00AM	Daxor Corporation Announces Further Acquisitions and Increased Utilization of its BVA-100® Blood Volume Diagnostic Throughout the U.S. (GlobeNewswire)
Jul-05-23 08:00AM	Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume Analyzer (GlobeNewswire)
Jun-22-23 04:15PM	Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering (GlobeNewswire)
Jun-20-23 08:00AM	Daxor Corporation to Showcase the Benefits of BVA-100® Guided Care at the American Association of Heart Failure Nurses (AAHFN) 19th Annual Meeting (GlobeNewswire)
Jun-15-23 08:00AM	Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services (GlobeNewswire)
Jun-12-23 08:00AM	Daxor Corporation to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-25-23 03:37PM	Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering (GlobeNewswire)
May-22-23 08:30AM	Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering (GlobeNewswire) -22.30%
May-19-23 04:53PM	Daxor Corporation Announces Proposed Underwritten Public Offering (GlobeNewswire) -6.06%
May-18-23 08:00AM	New Study Demonstrates Clinical Utility of Daxors Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes (GlobeNewswire)
Apr-20-23 08:00AM	New Studies Presented at the 43rd International Society for Heart and Lung Transplant Validate the Applicability of the BVA-100® Blood Test for Patients with Advanced Heart Failure (GlobeNewswire)
Apr-17-23 08:00AM	Daxor Corporation to Exhibit at the MedAxiom Cardiovascular Transforum Conference Spring23 to Advance Awareness and Further Adoption of Daxors Blood Volume Diagnostic (BVA-100®) (GlobeNewswire)
Apr-13-23 08:00AM	Daxor Corporation to Exhibit at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions (GlobeNewswire)
Mar-27-23 08:00AM	Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100® Blood Volume Diagnostic for Heart Failure Patients (GlobeNewswire) +15.89%
Mar-23-23 08:30AM	New Study Confirms Daxors BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients (GlobeNewswire)
08:00AM	Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients (GlobeNewswire)
Mar-03-23 08:00AM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
Mar-02-23 07:00AM	Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022 (GlobeNewswire) +5.46%
Mar-01-23 08:00AM	Daxor Corporation to Report Fiscal Year 2022 Financial Results on Wednesday, March 1, 2023 and Provide Corporate Update (GlobeNewswire)
Feb-17-23 08:00AM	Daxor Corporation Appoints Linda Cooper, Vice President Project Management (GlobeNewswire)

DAXOR Corporation is an innovative medical instrumentation and biotechnology company. DAXOR designed and developed the BVA-100 Blood Volume Analyzer. It is the first instrument approved by the FDA to provide rapid direct measurement of a patient's true blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. The BVA-100 is a semi-automated Blood Volume Analyzer. It is used in conjunction with a single use diagnostic kit. It is the first FDA-approved instrument to provide rapid direct measurement of a patient's blood volume.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Feldschuh Michael Richard	Chief Executive Officer	Apr 04 '25	Buy	7.89	2,063	16,277	212,694	Apr 07 03:23 PM
Michel Robert J	Chief Financial Officer	Mar 10 '25	Buy	8.00	1,000	8,000	17,050	Mar 11 09:36 AM
Feldschuh Michael Richard	Chief Executive Officer	Mar 10 '25	Buy	7.68	3,360	25,805	210,852	Mar 11 09:36 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DXR

Daxor Corp

Upgrade your FINVIZ experience